Smoking is the leading cause of preventable death and disability in the United States, responsible for 1 in 5 deaths and a decrease in life expectancy by 10 years. Quitting smoking by age 40 reduces premature death by 90%. We are investigating novel treatments for smoking cessation, particularly among smokers who have difficulty accessing traditional smoking cessation services.
Ongoing Studies
5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder
(Site PI: Peter Hendricks; PI: Matthew Johnson Johns Hopkins University; U01DA052174)
We propose a multi-site, double-blind, randomized clinical trial of the 5-HT2A receptor agonist psilocybin for smoking cessation. A diverse sample with regard to ethnoracial identity and SES will be recruited at each site with compensation for study visits. The proposed double-blind study will treat 66 participants (22 at each site), randomized to receive either:
- psilocybin; 20 mg/70 in session 1 and 30 mg/70 kg in session 2, with sessions 1 week apart; or
- niacin; 250 mg in session 1 and 375 mg in session 2, with sessions 1 week apart.
We hypothesize that psilocybin will be associated with improved cognitive control and decreased anticipation of withdrawal relief (from smoking) 1 day after the target quit date, which will be associated with greater 7-day point-prevalence abstinence at 12- month follow-up.
Link to abstract in NIH ReporterLearn more about Peter Hendricks
Adaptation and Evaluation of a Culturally- and Gender-Relevant Tobacco Cessation among Women in Brazil: An Integrated mHealth Approach
(PI: Dr. Isabel Scarinci; R21CA253574)
We developed and established the efficacy of a theory-based, culturally- and gender-relevant Community Health Worker (CHW) intervention for low-income Brazilian women that augments the tobacco cessation program offered through the public health system. This application represents the continuation of our gender-relevant tobacco control efforts in Brazil by proposing the adaptation of this CHW-delivered tobacco cessation program to be integrated with mHealth support through mobile devices (App).
Link to abstract in NIH ReporterLearn more about Isabel Scarinci
IN VIVO EXPERIENCE WITH NRT TO INCREASE ADHERENCE AND SMOKING ABSTINENCE
(PI: Dr. Karen Cropsey; R01DA039678)
The current project is a randomized controlled trial to maximize combination NRT medication adherence with smokers by testing an In Vivo NRT experiential intervention in which participants use the medication in session and describe expectancies and experiences with the medication. Outcomes of interest are smoking abstinence and medication adherence.
Link to abstract in NIH ReporterLearn more about Karen Cropsey
NRT SAMPLING AND SELECTION TO INCREASE MEDICATION ADHERENCE
(PI: Dr. Karen Cropsey; R34DA043346)
This is a pilot trial to maximize medication adherence with low income smokers by testing an in vivo NRT experiential intervention. Smokers will sample four different short-acting NRT products (gum, lozenge, nasal spray, inhaler, counterbalanced within participant across sessions) in combination with nicotine patch in session. Primary outcomes include feasibility and acceptability of this novel intervention as well as medication adherence.
Link to abstract in NIH ReporterLearn more about Karen Cropsey
EFFECTIVENESS OF A SMOKING CESSATION ALGORITHM INTEGRATED INTO HIV PRIMARY CARE
(MPI: Dr. Karen Cropsey; Conall O’Cleirigh (Mass General Hospital); Heidi Crane (University of Washington); R01DA044112)
The purpose of this proposal is to conduct a mixed efficacy/effectiveness trial comparing an algorithm treatment (AT) decisional aid to help providers prescribe smoking cessation pharmacotherapy to an enhanced Treatment as Usual (quit line referral only; eTAU) group. The primary outcome will be point prevalence smoking abstinence at 6 months. Other smoking-related outcomes of interest include 24-hour quit attempts and reduction in cigarettes smoked per day.
Link to abstract in NIH ReporterLearn more about Karen Cropsey
EFFECTIVENESS OF A SMOKING CESSATION ALGORITHM INTEGRATED INTO HIV PRIMARY CARE
(MPI: Dr. Karen Cropsey; Conall O’Cleirigh (Mass General Hospital); Heidi Crane (University of Washington); R01DA044112A1-S1)
This diversity supplement will provide training and experience to Dr. Samantha Hill in the area of co-use of cannabis and tobacco. In particular, this supplement will examine smoking cessation among 18-24 year old smokers living with HIV who co-use cannabis and will use formative methods to determine how to best deliver tobacco interventions to PLWH who co-use cannabis and tobacco.
Link to abstract in NIH ReporterLearn more about Karen CropseyLearn more about Samantha Hill
A PILOT TRIAL COMPARING NICOBLOC TO NICOTINE LOZENGES: INITIAL ACCEPTABILITY AND FEASIBILITY TRIAL
(PI: Dr. Karen Cropsey)
This pilot study will examine the feasibility, acceptability, and preliminary impact of using NicoBloc compared to nicotine lozenges. Forty (n=40) participants will be randomized to one of two interventions:
- NicoBloc or
- nicotine lozenge
All participants will complete approximately 60 minutes of baseline assessment to determine smoking history and characteristics prior to randomization, including previous experience with NRT.
Circadian and sleep mechanisms among racial groups for nicotine dependence, craving and withdrawal
(MPI: Dr. Karen Cropsey; Dr. Karen Gamble; R01DA046096-01A1)
This five year R01 project will examine the relationship between sleep behavior and circadian misalignment on tobacco use including nicotine dependence, withdrawal and cravings.
Link to abstract in NIH ReporterLearn more about Karen CropseyLearn more about Karen Gamble
THE TIME COURSE AND CLINICAL SIGNIFICANCE OF EARLY E-CIGARETTE WITHDRAWAL EFFECTS
(PI: Dr. Peter Hendricks; R01DA036027)
The objectives of the proposed project are to:
- characterize the early time course of e-cigarette withdrawal effects;
- evaluate the clinical significance of early e-cigarette withdrawal effects;
- compare the time course and clinical significance of early e-cigarette withdrawal effects to the time course and clinical significance of early tobacco withdrawal effects; and
- examine moderators of the time course and clinical significance of early e-cigarette withdrawal effects.
Link to abstract in NIH ReporterLearn more about Peter Hendricks
EARLY WITHDRAWAL EXPOSURE AND NEGATIVE AFFECT WITHDRAWAL (NAW) REGULATION TRAINING FOR SMOKING CESSATION
(PI: Dr. Peter Hendricks; R01DA045186-01A1)
The primary goal of this investigation is to evaluate an early withdrawal exposure plus negative affect withdrawal regulation training intervention for smoking cessation. Specific aims include evaluating the efficacy of the treatment components and investigating potential mediators and moderators of the treatment components.
Link to abstract in NIH ReporterLearn more about Peter Hendricks
DEVELOPMENT, IMPLEMENTATION, AND EVALUATION OF A SMOKING CESSATION INTERVENTION TAILORED TO RURAL YOUNG ADULT AFRICAN AMERICAN MEN: TOWARD SCALABILITY
(PI: Dr. Isabel Scarinci; R21CA217638)
The overall goal of this feasibility study is to make adaptations to evidence-based approaches, and develop, implement, and examine the feasibility and scalability of a theory-based, culturally relevant smoking cessation intervention for young adult AA men in rural Alabama who smoke cigarettes. The primary outcome will be 7-day point prevalence abstinence (defined as no cigarettes in the past 7 days and verified through measurement of exhaled carbon monoxide levels) at 6- month follow-up.
Link to abstract in NIH ReporterLearn more about Isabel Scarinci
NETWORK FOR TOBACCO CONTROL AMONG WOMEN IN ANTIOQUIA, COLOMBIA
(PI: Dr. Isabel Scarinci; R21TW010637)
The overall purpose of the Network for Tobacco Control among Women in Antioquia, Colombia, is to establish community and institutional capacity to promote gender-relevant tobacco control efforts among Colombian women. The goals of the “Network” are to reduce tobacco use and exposure to environmental tobacco smoke among women in Antioquia.
Link to abstract in NIH Reporter Learn more about Isabel Scarinci
DEVELOPMENT, IMPLEMENTATION, AND EVALUATION OF A TOBACCO CESSATION INTERVENTION TAILORED TO PERSONS LIVING WITH HIV (PLWH) IN BRAZIL: A FEASIBILITY STUDY
(PI: Dr. Isabel Scarinci; Funding: NIDA; R21DA049557)
This project seeks to refine and pilot test a novel smoking cessation intervention tailored to the unique needs or Brazilian smokers engaged in care for their HIV disease.
Link to abstract in NIH Reporter Learn more about Isabel Scarinci